Kiora Pharmaceuticals (KPRX) Total Liabilities (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Total Liabilities came in at $7.3 million in Q1 2026, down 29.33% YoY from $10.3 million in Q1 2025, and down 10.27% on a QoQ basis from $8.1 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Total Liabilities (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Total Liabilities data on file, last reported at $7.3 million in Q1 2026.
- Quarterly Total Liabilities fell 29.33% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (down 29.33% YoY) and the FY2025 annual result came in at $8.1 million, down 24.22% from the prior year.
- Total Liabilities slipped to $7.3 million in Q1 2026, from $8.1 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $10.7 million in Q4 2024 to a low of $6.2 million in Q2 2023.
- A 5-year average of $7.8 million and a median of $7.5 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 376.39% — and 2026, when it declined 29.33%.
- Tracing KPRX's Total Liabilities over 5 years: stood at $7.3 million in 2022, then gained by 4.56% to $7.6 million in 2023, then jumped by 41.07% to $10.7 million in 2024, then retreated by 24.22% to $8.1 million in 2025, then fell by 10.27% to $7.3 million in 2026.
- The last three Total Liabilities figures came in at $7.3 million (Q1 2026), $8.1 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | 6.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.92 Mn |
| Mar 31, 2026 | 7.29 Mn |
| Dec 31, 2025 | 8.13 Mn |
| Sep 30, 2025 | 7.45 Mn |
| Jun 30, 2025 | 9.82 Mn |
| Mar 31, 2025 | 10.32 Mn |
| Dec 31, 2024 | 10.72 Mn |
| Sep 30, 2024 | 8.48 Mn |
| Jun 30, 2024 | 7.71 Mn |
| Mar 31, 2024 | 7.54 Mn |
| Dec 31, 2023 | 7.60 Mn |
| Sep 30, 2023 | 7.79 Mn |
| Jun 30, 2023 | 6.24 Mn |
| Mar 31, 2023 | 6.37 Mn |
| Dec 31, 2022 | 7.27 Mn |
| Sep 30, 2022 | 7.14 Mn |
| Jun 30, 2022 | 6.70 Mn |
| Mar 31, 2022 | 6.38 Mn |
| Dec 31, 2021 | 5.55 Mn |
| Sep 30, 2021 | -2.58 Mn |